中药及其活性成分对绝经后骨质疏松症的治疗及其作用机制  

Effect and mechanism of traditional Chinese medicine and their active constituents in postmenopausal osteoporosis

作　　者：赵丕文[1,2] 牛建昭[1] David Yue-Wei Lee 王继峰[1] 孙艳玲[1] 李亚东[1] 

机构地区：[1]北京中医药大学基础医学院,北京100029 [2]Mclean Hospital,Belmont,MA 02478

出　　处：《中国中药杂志》2012年第12期1693-1699,共7页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金项目(30772849);高等学校创新引智计划(B07007);北京中医药大学自主科研课题(JYBZZ-JS014)

摘　　要：绝经后骨质疏松症是更年期妇女的常见全身性骨代谢疾病,体内雌激素水平下降是其重要病因。激素替代疗法(HRT)虽然在多年的临床实践中有着良好和肯定的疗效,但其在提高妇科肿瘤发生率等方面具有明显的副作用。临床实践已经证明,多种妇科中药方剂、单味中药及中药植物雌激素样活性成分对骨质疏松症有确凿疗效且副作用小。其主要通过作用于靶组织、靶细胞的雌激素受体并进而影响其下游信号传导通路中骨代谢相关调节蛋白和因子的表达情况,达到对骨质疏松症的防治效果。同时,近年来雌激素相关受体的研究也为全面揭示中药及其活性成分抗骨质疏松症的作用机制提供了新的可能角度和途径。Postmenopausal osteoporosis is one of the commonest systemic bone metabolism diseases among menopausal women, mainly caused by lowering internal estrogen. Although Hormone Replacement Therapy （HRT） is an effective method in clinical prac- tice for years, it shows side-effect in increasing gynecological carcinoma. It has already been proved by clinical tests that multiple tradi- tional Chinese medicine formulas and their monomer ingredients and phytoestrogen-like active constituents contained in traditional Chi- nese medicines are effective on treating osteoporosis with relatively less side-effects comparing with HRT. They show proteetive and therapeutic effects by acting on estrogen receptors of targeted tissues and targeted cells and then affecting expressions of bone metabo- lism-related regulatory proteins and factors in downstream signal conduct paths. Recent studies on estrogen related receptor （ERR） provide new possibilities and pathways for mechanism of traditional Chinese medicine and their active constituents in osteoporosis.

关 键 词：妇科中药 活性成分 绝经后骨质疏松症 植物雌激素 雌激素受体 雌激素相关受体 

分 类 号：R580[医药卫生—内分泌]